ID   SW872
AC   CVCL_1730
SY   SW-872; SW 872
DR   BTO; BTO:0003743
DR   CLO; CLO_0009201
DR   CLO; CLO_0037071
DR   EFO; EFO_0002373
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-92
DR   BCRC; 60432
DR   BioSample; SAMN03472763
DR   cancercelllines; CVCL_1730
DR   Cell_Model_Passport; SIDM01159
DR   ChEMBL-Cells; CHEMBL3308837
DR   ChEMBL-Targets; CHEMBL2366302
DR   CLS; 300405
DR   Cosmic; 684521
DR   Cosmic; 909756
DR   Cosmic; 923383
DR   Cosmic; 2009544
DR   Cosmic; 2307722
DR   Cosmic; 2560246
DR   Cosmic; 2800532
DR   Cosmic-CLP; 909756
DR   DepMap; ACH-002310
DR   EGA; EGAS00001000978
DR   GDSC; 909756
DR   GEO; GSM185156
DR   GEO; GSM185157
DR   GEO; GSM482514
DR   GEO; GSM1543668
DR   GEO; GSM1543669
DR   GEO; GSM1670514
DR   IARC_TP53; 24518
DR   IGRhCellID; SW872
DR   IZSLER; BS TCL 119
DR   LINCS_LDP; LCL-1459
DR   Lonza; 88
DR   NCBI_Iran; C638
DR   PharmacoDB; SW872_1547_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1730
DR   PubChem_Cell_line; CVCL_1730
DR   Wikidata; Q54971215
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=3518877;
RX   PubMed=6220172;
RX   PubMed=12068308;
RX   PubMed=16888811;
RX   PubMed=17354236;
RX   PubMed=17426441;
RX   PubMed=17431109;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22911243;
RX   PubMed=24726063;
RX   PubMed=24758355;
RX   PubMed=26643872;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   From: Scott and White Clinic; Temple; USA.
CC   Population: Caucasian.
CC   Doubling time: 24 hours (PubMed=16888811).
CC   HLA typing: A*02:01:01G; B*27:05:02,40:01:02; C*01:02:01,03:04:01; DPB1*02:01:02; DQA1*04:01:01,05:05:01; DQB1*03:01:01,04:02:01; DRB1*08:01:01;13:03:01 (CLS=300405).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (ATCC).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=26643872; ATCC; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (PubMed=26643872; ATCC; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Asn (c.752T>A); ClinVar=VCV000528254; Zygosity=Homozygous (PubMed=16888811; PubMed=26643872; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.25%; Native American=0%; East Asian, North=2.4%; East Asian, South=0.14%; South Asian=1.73%; European, North=69.64%; European, South=24.84% (PubMed=30894373).
CC   Misspelling: SW672; PubMed=17431109.
ST   Source(s): ATCC; CLS; Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 9,12
ST   D18S51: 12,16
ST   D21S11: 27,31.2
ST   D3S1358: 16
ST   D5S818: 12,13
ST   D7S820: 8,11
ST   D8S1179: 12,15
ST   FGA: 21.2,23
ST   Penta D: 9,10
ST   Penta E: 5,10
ST   TH01: 8,10
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C3194; Liposarcoma
DI   ORDO; Orphanet_69078; Liposarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   36Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 39
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=16888811; DOI=10.1002/jcb.21073;
RA   Moneo V., Serelde B.G., Fominaya J.M., Martinez-Leal J.F.,
RA   Blanco-Aparicio C., Romero L., Sanchez-Beato M., Cigudosa J.C.,
RA   Tercero J.C., Piris M.A., Jimeno J.M., Carnero A.;
RT   "Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged
RT   sarcoma cell lines correlates with mutated p53.";
RL   J. Cell. Biochem. 100:339-348(2007).
//
RX   PubMed=17354236; DOI=10.1002/ijc.22643;
RA   Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G.,
RA   Myklebost O.;
RT   "Potential for treatment of liposarcomas with the MDM2 antagonist
RT   Nutlin-3A.";
RL   Int. J. Cancer 121:199-205(2007).
//
RX   PubMed=17426441; DOI=10.4161/cbt.6.4.3816;
RA   LaPensee E.W., Reddy S.P., Hugo E.R., Schwemberger S.J.,
RA   Ben-Jonathan N.;
RT   "LS14 cells: a model for chemoresistance in liposarcoma.";
RL   Cancer Biol. Ther. 6:519-524(2007).
//
RX   PubMed=17431109; DOI=10.1158/1535-7163.MCT-06-0729;
RA   Moneo V., Serelde B.G., Leal J.F.M., Blanco-Aparicio C.,
RA   Diaz-Uriarte R., Aracil M., Tercero J.C., Jimeno J.M., Carnero A.;
RT   "Levels of p27(kip1) determine Aplidin sensitivity.";
RL   Mol. Cancer Ther. 6:1310-1316(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22911243; DOI=10.1155/2012/148614;
RA   Stratford E.W., Castro R., Daffinrud J., Skarn M., Lauvrak S.,
RA   Munthe E., Myklebost O.;
RT   "Characterization of liposarcoma cell lines for preclinical and
RT   biological studies.";
RL   Sarcoma 2012:148614.1-148614.9(2012).
//
RX   PubMed=24726063; DOI=10.1186/1756-9966-33-33;
RA   Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B.,
RA   Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R.,
RA   Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.;
RT   "TERT promoter hotspot mutations are recurrent in myxoid liposarcomas
RT   but rare in other soft tissue sarcoma entities.";
RL   J. Exp. Clin. Cancer Res. 33:33.1-33.8(2014).
//
RX   PubMed=24758355; DOI=10.1186/1471-2407-14-281;
RA   Moneo V., Serelde B.G., Blanco-Aparicio C., Diaz-Uriarte R.,
RA   Aviles P., Santamaria G., Tercero J.C., Cuevas C., Carnero A.;
RT   "Levels of active tyrosine kinase receptor determine the tumor
RT   response to Zalypsis.";
RL   BMC Cancer 14:281.1-281.10(2014).
//
RX   PubMed=26643872; DOI=10.18632/oncotarget.6464;
RA   Kanojia D., Nagata Y., Garg M., Lee D.H., Sato A., Yoshida K.,
RA   Sato Y., Sanada M., Mayakonda A., Bartenhagen C., Klein H.-U.,
RA   Doan N.B., Said J.W., Mohith S., Gunasekar S., Shiraishi Y., Chiba K.,
RA   Tanaka H., Miyano S., Myklebost O., Yang H., Dugas M.,
RA   Meza-Zepeda L.A., Silberman A.W., Forscher C., Tyner J.W., Ogawa S.,
RA   Koeffler H.P.;
RT   "Genomic landscape of liposarcoma.";
RL   Oncotarget 6:42429-42444(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//